Age: 58
male
Adam McKay (born April 17, 1968) is an American screenwriter, producer, and director. McKay began his career as a head writer for the NBC sketch comedy show Saturday Night Live (SNL) from 1995 to 2001. After leaving SNL, McKay collaborated with comedian Will Ferrell on his comedy films Anchorman: The Legend of Ron Burgundy (2004), Talladega Nights: The Ballad of Ricky Bobby (2006), and The Other Guys (2010). Ferrell and McKay later co-wrote and co-produced numerous television series and films, with McKay himself co-producing their website, Funny or Die, through their company, Gary Sanchez Productions. Aside from working with Ferrell, McKay wrote and directed the satirical films The Big Short (2015), Vice (2018), and Don't Look Up (2021). McKay won an Academy Award, a BAFTA, and a Critics' Choice Award for adapting the screenplay of The Big Short. In 2019, McKay founded Hyperobject Industries, a production company. Description above from the Wikipedia article Adam McKay, licensed under CC-BY-SA, full list of contributors on Wikipedia.
Currently in production now. The full inside story of the breathtaking rise and shocking collapse of a multibillion-dollar startup, by the prize-winning journalist who first broke the story and pursued it to the end in the face of pressure and threats from the CEO and her lawyers. In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood tests significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work. For years, Holmes had been misleading investors, FDA officials, and her own employees. When Carreyrou, working at The Wall Street Journal, got a tip from a former Theranos employee and started asking questions, both Carreyrou and the Journal were threatened with lawsuits. Undaunted, the newspaper ran the first of dozens of Theranos articles in late 2015. By early 2017, the company's value was zero and Holmes faced potential legal action from the government and her investors. Here is the riveting story of the biggest corporate fraud since Enron, a disturbing cautionary tale set amid the bold promises and gold-rush frenzy of Silicon Valley.
